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In the past three decades, the application of information derived from cardiovascular research markedly reduced the death rate from ischemic heart disease, the number one killer in the Western world. This resulted, in part, from the integration and focusing of innovative techniques developed and employed by well trained investigators enticed from multiple scientific and clinical disciplines. Throughout this interval, it was perhaps appropriate on the basis of priority that another group of cardiac diseases referred to as cardiomyopathies received very little attention. A second, perhaps more legitimate, reason for this lack of attention is that many of these diseases, at least in this country, are inherited and until recently, techniques were not available to identify the underlying genetic defect. The introduction of recombinant DNA techniques in the 1970s followed by their application in molecular genetics drastically changed the potential to explore the molecular basis of these disorders. Previously, unless one knew the protein defect responsible for the inherited disorder, it was almost impossible to identify the gene. The development of linkage analysis makes it possible to map the chromosomal locus of a disease related gene Phe513Cys or Leu'8Val, predict a benign prognosis. '6 In the very elegant study by Fananapazir and Epstein17 in this issue of Circulation, the investigators have again confirmed the important correlations between specific mutations and prognosis. They report on a mutation in which glycine substitutes for glutamic acid (Gly'56Glu) in a large family of 245 kindred that shows essentially a benign prognosis. They confirm that Arg4'Gln in those families of North American descent have a high incidence of sudden cardiac death, high penetrance, and early onset of disease. In the mutation, Leu`8Val, they report only 8% dead by the age of 50 years, indicating that the prognosis is benign as previously reported. Nevertheless, on the basis of results of this study, the investigators challenge some of the concepts that have been emerging over the genotypephenotype correlations in HCM. The investigators question the claim that a mutated amino acid with a charge is predictive of a malignant prognosis and suggest that it is no longer tenable. This is based on their findings that the mutation Gly'56Glu, which does involve a negatively charged amino acid, glutamic acid, has a benign prognosis. Second, the mutation Val'Met, which has no change in charge, has a relatively poor prognosis in that 50% of the individuals with this clearly challenge the concept that charge is not the only determinant of a poor prognosis, and as pointed out by the investigators, the position of the change is also likely to be a determinant independent of whether the amino acid is charged or neutral. The other related observation by the investigators is the finding of the mutation, Arg`'Gln, in a Korean family that appears not to be associated with a severe prognosis. In all other reported families this mutation is associated with an unfavorable prognosis. As indicated by the investigators, however, it is a small family (eight kindred) and the possibility of sudden death occurring with further observation cannot be excluded. It could, however, employ another intriguing possibility: the deleterious nature of the mutation requires an interaction with other genes found in the Caucasian genotype and not in the Korean genotype. If such should be the case, insights to be gleaned may have important implications for polygenic disorders such as hypertension and ischemic heart disease. Last, the investigators give the impression that the prognosis when stratified for benign or malignant must be all or nothing, which in fact is not the case as clinical studies have documented that certain mutations predict a prognosis between malignant and benign as indicated by the studies'6 on Arg249Gln. In summary, the data in this study support the important observation that there is a definite correlation between specific mutations and the incidence of sudden death as well as the severity of the disease. It is perhaps important to point out that of 35 reported mutations in the I3MHC gene, 19 involve a charged amino acid of which 11 of them involve the positively charged arginine. The benign prognosis associated with Gly16Glu may reflect that the amino acid, glutamic acid, is negatively instead of positively charged.
The somewhat surprising statement in this article is the authors' concluding sentence: "Thus, although it is reasonable to genotype other family members when a mutation is discovered, we feel that until more is known about the correlations between the phenotype and genotype and mutation-specific causes of sudden cardiac death, routine genotyping of HCM patients will add little to their care and divert resources from more useful approaches to the diagnosis and treatment of this disease." This is contrary to this investigator's opinion as I There is another equally important reason not to halt the search for mutations in 3MHC and other genes responsible for HCM. The time is rapidly approaching when more definitive therapy will be available; perhaps even for those adults who already have the disease. We nant disease, there is one normal gene (allele) and one abnormal gene (allele) and that the time is rapidly approaching when it will be possible to inhibit the mutant allele and permit only the normal allele to transcribe its normal protein. Although it is not a proliferating organ, the heart "turns over" every few weeks or months because practically all proteins of the heart have half lives of hours and certainly not more than days. Because the heart replaces itself even in the adult, if the mutant allele is inhibited and only the normal protein is translated it is quite conceivable that within months to a year the new heart would be made from normal 3MHC and devoid of the abnormal. Whether this is achieved through antisense mRNA, triple-helix inhibitor, or other as yet unknown genetic weapons, it is very likely that such therapy is forthcoming in the early part of the 20th century. It is also conceivable that within the next decade gene replacement therapy or other means will be possible. It "Nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten path; nor is there any better way to advance the proper practice of medicine than to give our minds to the discovery of the usual law of Nature by careful investigation of cases of rare forms of diseases. For it has been found that in almost all things, that what they contain of useful or applicable nature is hardly perceived unless we are deprived of them, or they become deranged in some way." Identifying the mutations responsible for hypertrophic cardiomyopathy has not yet provided important clues to understanding cardiac growth but it still may as we discover more of the mutations in the ,BMHC and other genes responsible for this disease. The three dimensional structure of JMHC protein has just been derived from X-ray crystalography,18 which, together with the functional information to be gained from point mutation, should rapidly accelerate structure function analysis of this important molecule. Myosin is the motor driving contractility of the heart and is also the major motor for contractility in all muscles. HCM is now known to be genetically heterogeneous with three other loci having been mapped (lq, llq, 15q)19-2' and other loci yet to be identified22; however, no other genes have yet been isolated. Ultimately, not only will all of the molecular defects be identified but so will the pathogenesis of the resulting biochemical, pathological, and clinical abnormalities. These should come together to provide clues fundamental to our understanding of cardiac growth and usher in a new era providing us with the first important key to the cascade that modulates cardiac growth. In contrast to the conclusion by Fananapazir and Epstein, I would strongly recommend that we relentlessly pursue the search to identify all mutations in the /3MHC gene and other genes responsible for HCM. We must continue the march forward not only must realize that because HCM is an autosomal domi-for the sake of individuals who may be impaired as a result of their unfortunate random hit by the mutagen, but also for its other potential implications that may be displayed as a result of this unconventional pathway not so often tread. The long-term response of the heart to all forms of injury whether it be hypertension or myocardial infarction is increased muscle mass (hypertrophy) and/or dilatation. Nature has modeled pure forms of these two responses in the form of familial HCM (hypertrophy) and familial dilated cardiomyopathy (dilatation). Elucidation of the pathogenesis of these diseases should provide insight into cardiac development, its architectural design, and the remodeling response to acquired injury.
